CClinicalTrials.gg
Status unknownNCT01800513EMBX/IVFUpdated Feb 27, 2013

Endometrial Biopsy Prior to IVF in Those Patients With Prior Implantation Failure

An interventional study of Endometrial Biopsy and Sham Procedure in Implantation Failure and Infertility, sponsored by Shady Grove Fertility Reproductive Science Center. Status unknown at 1 site in United States. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2013-02-27.

Sponsored by Shady Grove Fertility Reproductive Science Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2013), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Study summary

This proposed research is a single center, prospective, single-blinded, randomized controlled trial, designed to evaluate IVF pregnancy outcomes following endometrial injury in 254 patients with implantation failure. Patients will be identified during their work-up and treatment at Shady Grove Fertility Reproductive Science Center. Only Shady Grove patients are eligible for the study. The investigators hypothesize in patients with one or more previous failed day 5 blastocyst transfers, injury to the endometrium via endometrial biopsy will improve clinical pregnancy outcomes compared to controls.

Read the detailed description

Despite advances in assisted reproductive technologies; implantation failure in patients undergoing in-vitro fertilization (IVF) is frequent. Unfortunately, few treatments exist except for the use of a gestational carrier. There have been a number of recent clinical studies demonstrating that local injury to the endometrium results in improved clinical pregnancy outcomes for patients with a history of implantation failure. However, not all studies have shown a beneficial effect, and those demonstrating benefit have been limited by small sample sizes, and considerable heterogeneity in the procedures and populations evaluated. A recent meta-analysis synthesized the available data concluded that a large, prospective, well-designed randomized trial is desperately needed to definitively assess this new possible treatment. If these preliminary findings from previous trials are confirmed, this practice could be applied in the clinical setting to help patients suffering from repeated implantation failures.

02

Conditions studied

  • Implantation Failure
  • Infertility

Browse trials for

Keywords

  • Implantation Failure
  • In-vitro Fertilization
  • Infertility
  • Endometrial Biopsy
03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's planned enrollment of 254 is above the median of 120 across 1,698 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Shady Grove Fertility Reproductive Science Center is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women age 18-37
  • One or more previous implantation failures with autologous fresh or frozen blastocyst transfer
  • Undergoing fresh autologous IVF cycle
  • No other current uterine (i.e.: uterine fibroids, polyps), hematologic, or genetic causes for infertility and implantation failure
  • One or more good quality blastocyst(s) available for transfer

Exclusion criteria

Exclusion Criteria:

  • Those unable to comprehend the investigational nature of the proposed study
  • Positive pregnancy test
  • Possible causes for impaired implantation (systemic disease, endometriosis, ultrasound evidence of current hydrosalpinx, uterine polyps, uterine myomas (fibroids), uterine cavity malformations or Asherman's syndrome)
  • Poor responders, defined as FSH >12 on day 3 or less than 4 follicles on a previous IVF cycle
  • BMI >30 or \<18
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
254 participants (estimated)

Study arms

  • Experimental
    Endometrial Biopsy

    Subjects will have a vaginal speculum placed and visualization of the cervix will be obtained. The cervix will be cleaned with betadine (or hibiclens for those with an iodine allergy). Those randomized to the treatment arm (endometrial biopsy) will have an endometrial pipelle (Endocell, Wallach, Orange, Connecticut) inserted gently through the cervix into the uterus. Two passes will be performed with the pipelle catheter. For each pass the catheter will be rotated and scraped 4 times, once in each quadrant.

    Procedure: Endometrial Biopsy

  • Sham comparator
    Control

    Those randomized to the control group will have a small cotton swab placed gently into the cervix. No tissue will be obtained with this method. The randomization to a placebo control is necessary to prove that any positive effects seen are due to the biopsy and not just random chance.

    Procedure: Sham Procedure

Interventions

  • ProcedureEndometrial Biopsy

    Also known as: Endometrial Pippelle Biopsy Catheter

  • ProcedureSham Procedure
06

What researchers measure

Primary outcomes

  1. The primary outcome measurement in this study is clinical pregnancy rate, which is defined as identification of a fetal heart beat on ultrasound.

    Time frame: 8-10 weeks after embryo transfer

Secondary outcomes

  1. implantation rate

    Time frame: 8-10 weeks after embryo transfer

  2. miscarriage rate

    Time frame: 2 years

  3. multiple gestation rate

    Time frame: at delivery

  4. endometrial thickness during stimulation

    Time frame: during stimulation

  5. Live Birth rate

    Time frame: 10 months after IVF cycle

07

Study locations

1 of 1 sites recruiting
  • Shady Grove Fertility Reproductive Science Center
    Rockville, Maryland 20850, United States
    Recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01800513
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Responsible party
Ryan Heitmann (REI Clinical Fellow, Shady Grove Fertility Reproductive Science Center) — Principal investigator
First posted
Feb 27, 2013
Start date
Feb 2013
Primary completion
Dec 2014 (estimated)
Completion
Dec 2015 (estimated)
Last update
Feb 27, 2013

Study contacts

Erin F Wolff, M.D.
Contact
wolffe@mail.nih.gov
Erin F Wolff, M.D.
principal investigator · Shady Grove Fertility

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion